Neoplasms, Second Primary
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Drugs by status
Phase 4 trials (9)
Phase 3 trials (7)
Phase 2 trials (11)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (21)
- Novartis
- Corporacion Parc Tauli
- Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
- Hebei University
- Boston University
- Spanish Breast Cancer Research Group
- Universidad Autonoma de Madrid
- University of Seville
- University of Valencia
- University of Vigo
- Badalona Hospital Germans Trias i Pujol
- University of Orense
- Complejo Hospitalario La Mancha Centro
- University of Lyon
- Osakidetza
- University of Barcelona
- Universidad Autonoma de Barcelona
- Clinica Universidad de Navarra
- People's Liberation Army of China
- Shenzhen Fifth People's Hospital
- Universidad Carlos III Madrid
Organization Involved with Phase 3 Indications (59)
- Spectrum Pharmaceuticals
- Daiichi Sankyo
- Bristol-Myers Squibb
- Amgen
- Roche
- Sanofi
- Angiochem Inc
- Bayer
- Blue Earth Diagnostics
- Light Sciences Oncology
- Nektar Therapeutics
- Sirtex Medical
- Amarin
- National Cancer Institute (NCI)
- Maastricht University
- Arbeitsgruppe Lebermetastasen und Tumoren
- Blokhin's Russian Cancer Research Center
- ECOG-ACRIN Cancer Research Group
- Italian Network for Tumor Biotherapy
- Kunming Medical University
- NeuroVita Clinic
- Radboud University
- Rocky Mountain Cancer Centers
- Seoul National University
- Sichuan University
- University of Leeds
- University of Rochester
- University of Siena
- Utrecht University
- Dutch Colorectal Cancer Group
- +29 more
Organization Involved with Phase 2 Indications (145)
- Cytogen
- DFB Pharma
- Kadmon
- Biocompatibles International plc
- AstraZeneca
- Merck
- Merck Serono
- Pharmacyclics
- Exelixis
- MediGene
- MedImmune
- Pfizer
- AIO-Studien-gGmbH
- Aposense Ltd.
- Array BioPharma
- Betta Pharmaceuticals Co.,Ltd.
- EPS Corporation
- Endocyte
- GlaxoSmithKline
- Hengrui Therapeutics, Inc.
- Nanobiotix
- Philogen S.p.A.
- Reata Pharmaceuticals, Inc.
- Simcere Pharmaceutical Co., Ltd
- Wu Jieping Medical Foundation
- National Institutes of Health (NIH)
- National Cancer Institute, France
- Fondazione Giovanni Pascale
- Rongjie Tao
- Huazhong University of Science and Technology
- +115 more
Organization Involved with Phase 1 Indications (37)
- AbbVie
- Schering-Plough
- Eli Lilly
- Anza Therapeutics, Inc.
- BIND Therapeutics
- Cascadian Therapeutics Inc.
- CTI BioPharma
- Northwest Biotherapeutics
- PharmAbcine
- Tracon Pharmaceuticals Inc.
- Strategia Therapeutics
- Strike Bio, Inc.
- University of Pennsylvania
- Rockefeller University
- University of Arizona
- Cedars-Sinai Medical Center
- Johns Hopkins University
- Thomas Jefferson University
- University of South Florida
- Mayo Clinic
- University of California, Davis
- University of California, San Diego
- University of Chicago
- University of Colorado, Denver
- Navidea Biopharmaceuticals
- Covance
- City of Hope National Medical Center
- Baptist Health
- Mary Crowley Cancer Center
- AVEO Pharmaceuticals
- +7 more
Organization Involved with Other Experimental Indications (6)